Chronic pelvic pain, quality of life and sexual health of women treated with palmitoylethanolamide and alpha-lipoic acid
Open-label, no control groupHumansWith alpha-lipoic acid
This study tested palmitoylethanolamide together with alpha-lipoic acid. Its results cannot be assigned to palmitoylethanolamide alone. More combination studies.
- Design
- Open-label, no control group
- Subjects
- 56 women with endometriosis-associated pelvic pain
- Dose used in the study
- PEA 300 mg plus alpha-lipoic acid 300 mg twice daily
- Duration
- 9 months, assessed at 3, 6 and 9 months
- What was measured
- Pain VAS, SF-36 quality of life, Female Sexual Function Index, Female Sexual Distress Scale
What the authors reported
No change in any measure at 3 months. By 6 and 9 months, pain and all quality-of-life categories improved (p < 0.001), and the sexual function and distress scores improved from baseline.
Limits of this study
No control group, no blinding. Nine months is long enough for other treatments and the natural course to change symptoms. Two compounds combined. Funding not stated in the abstract.
Source
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.